NCT02147158.

Trial name or title	A Study of the Safety and Efficacy of Intermittent Ulipristal Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas
Methods	Randomised controlled trial
Participants	Cyclic abnormal uterine bleeding (heavy or prolonged) Menstrual blood loss (MBL) ≥ 80 mL in the first 8 days of menses Minimum of 1 discrete leiomyoma observable by transvaginal ultrasound
Interventions	Various permutations of ulipristal acetate 5 mg or 10 mg or placebo
Outcomes	Absence of bleeding (time frame: 12 weeks) Time to absence of bleeding (time frame: 12 weeks)
Starting date	January 2014
Contact information	Watson Pharmaceuticals
Notes